Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Inclusion Criteria:

Histologically proven prostate cancer
Know metastatic disease on previous imaging, or PSA value ⩾ 1 ng/ml;
Castration resistant disease with confirmed testosterone level =< 50 ng/ml under prior first-line androgen deprivation therapy (ADT)
New planned treatment with enzalutamide or abiraterone, darolutamide or apalutamide
Willingness to undergo ARSI throughout the duration of the study as prescribed by the treating uro-oncologist
Stated willingness to comply with continuation of ARSI treatment for the duration of the study
Provision of signed and dated informed consent form

Exclusion Criteria:

Inability to provide written informed consent
Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)
Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy
A baseline superscan pattern on bone scan
Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible